Adding Timolol and Acetazolamide in a Glaucoma Patient with Asthma, Sulfonamide Rash, and Renal Impairment
A 68-year-old man with primary open-angle glaucoma has intraocular pressure 34 mmHg in both eyes despite nightly latanoprost, with advanced cupping (cup-to-disc 0.9) and a central island of field. He has asthma and reports wheezing after a friend's propranolol tablet; he also had a generalized rash after sulfamethoxazole-trimethoprim two years ago. eGFR is 38 mL/min/1.73 m², potassium 4.9 mmol/L, bicarbonate 22 mmol/L. A resident proposes adding timolol maleate 0.5% twice daily and oral acetazolamide 250 mg four times daily while awaiting laser trabeculoplasty. The patient asks why not just use the strongest drops. He uses a corticosteroid inhaler for asthma and has no cardiac history.
1. Evaluate the proposed timolol and acetazolamide, including the pharmacologic and patient-specific reasons each is problematic.
Read the worked answer
Timolol
Timolol is a nonselective beta-adrenergic antagonist. Even ophthalmic drops reach the systemic circulation through the nasolacrimal duct and can cause bronchospasm. In a patient with asthma and a prior wheeze after propranolol, timolol is contraindicated; betaxolol is relatively beta1-selective but still carries risk and is not a safe default. Punctal occlusion reduces but does not eliminate absorption.
Acetazolamide
Acetazolamide inhibits carbonic anhydrase, reducing aqueous secretion, but it causes metabolic acidosis and renal potassium/bicarbonate wasting. With eGFR 38 and bicarbonate already 22 mmol/L, the patient is at high risk of symptomatic acidosis, paresthesia, fatigue, and electrolyte disturbance. Dose reduction does not reliably remove risk, and the four-times-daily regimen is poorly tolerated. It is not a good bridge to laser in this patient.
Conclusion
Both proposals should be rejected. The resident is choosing agents by potency rather than by contraindication profile. The patient's 'strongest drop' question should be answered by explaining that efficacy must be balanced against systemic toxicity, and that a safer combination plus definitive laser or surgery is preferable.
2. Recommend an alternative topical regimen with rationale, specifically addressing the sulfonamide rash and the need for additional pressure lowering.
Read the worked answer
Options
- Brimonidine 0.2% twice daily is a reasonable add-on: it reduces aqueous production and increases uveoscleral outflow without bronchospasm. Counsel about dry mouth, fatigue, and allergic conjunctivitis; avoid in infants.
- Bimatoprost 0.03% nightly could replace or supplement latanoprost if adherence to a single nightly prostaglandin is preferred, though it adds conjunctival hyperemia and periocular pigmentation. Switching within the prostaglandin class is reasonable if latanoprost tolerability is poor.
- Dorzolamide is a topical carbonic anhydrase inhibitor and a sulfonamide derivative. Cross-reactivity with sulfonamide antibiotics is uncommon but not zero, and this patient had a generalized rash. I would avoid it or use it only with explicit counseling and a low threshold to stop, because safer alternatives exist.
- Pilocarpine is effective but causes miosis, dim vision, and brow ache; it is a poor choice in a patient with a central island.
Rationale
Add a drug from a different class with a favorable systemic profile, then proceed to laser trabeculoplasty rather than relying on chronic systemic therapy. If IOP remains uncontrolled, filtration surgery should be discussed. The sulfonamide history should be documented as a caution, not treated as an absolute contraindication to every sulfonamide-containing drop, but the risk-benefit balance favors avoiding dorzolamide here.
3. What monitoring and counseling would you provide, and what would make you stop the new drop?
Read the worked answer
Monitoring
- Check IOP 4–6 weeks after each change; a 20–30% reduction from 34 mmHg is the target, not a single 'normal' reading.
- Repeat visual field and optic disc assessment to confirm functional stability.
- If any sulfonamide-containing drop is used, monitor for rash, fever, and ocular allergy; stop immediately if mucosal or systemic symptoms occur.
- Check potassium, bicarbonate, and renal function only if a systemic carbonic anhydrase inhibitor is unavoidable; otherwise they are not needed for topical brimonidine or prostaglandin.
- Ask about wheeze, breathlessness, and night-time cough at every visit.
Counseling
- Demonstrate punctal occlusion for 1–2 minutes after instillation to reduce systemic absorption.
- Explain that brimonidine can cause fatigue and dry mouth but usually settles; report eye redness or swelling.
- Do not stop latanoprost abruptly; nightly dosing is important for prostaglandin receptor effects.
- Emphasize that laser is definitive adjunct therapy, not a sign of failure.
Stop criteria
Stop brimonidine for allergic conjunctivitis, persistent fatigue, or hypotension; stop any new agent for rash, bronchospasm, or paradoxical IOP rise.